Caroline Baumal is Chief Medical Officer at Apellis Pharmaceuticals, Inc. (APLS). They have made 6 open-market trades across 1 company since 2024, most recently 2026-05-14.
CIK 0001961100
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| APLS | 41,250 | $1.7M |
Shares reported on the most recent Form 4, priced at the 2026-05-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APLS | SELL | 2026-01-22 | 2026-01-23 | $21.77 | $61K | +7.2% | +4.1% | +89.6% |
| APLS | SELL | 2026-01-20 | 2026-01-21 | $19.79 | $37K | +9.0% | +6.3% | +95.4% |
| APLS | SELL | 2026-01-05 | 2026-01-06 | $25.53 | $77K | -17.0% | -6.1% | +69.1% |
| APLS | SELL | 2025-01-17 | 2025-01-21 | $29.96 | $111K | -3.4% | -5.6% | -39.9% |
| APLS | SELL | 2025-01-06 | 2025-01-08 | $33.81 | $190K | +1.3% | -2.0% | -37.7% |
| APLS | SELL | 2024-01-04 | 2024-01-05 | $60.05 | $330K | +7.6% | +14.8% | -5.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.